ClinicalTrials.gg
Enrolling by invitationNCT06722313Updated Dec 9, 2024

Optimized PGT-M Strategy for Patients with No Proband

An interventional study of Gametes (sperm or second polar bodies, MI eggs) or arrested embryos were reserved for identification of a proband in De Novo Mutation, Preimplantation Genetic Testing and Without Proband, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Enrolling by invitation at 1 site in China. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 1 year 11 months after the study started (first participant enrolled Jan 2023, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Sex
All
01

Study summary

The clinical practice of PGT-M for monogenetic disease usually adopted a double-checking strategy, which detect the mutation by Sanger sequencing and meantime construct haplotypes using the DNA sample of the proband so as to avoid the risks of misdiagnosis due to recombination and allele drop out (ADO). When there is no affected parent or offspring to serve as the proband, embryo carriers identified through direct mutation detection can be preferentially taken as probands for subsequent linkage analysis. In cases where none of the embryos are detected as mutant carrier, single sperm or the second polar body (PB2) can be complementally collected in the work-up of haplotype establishment. Our study aims to develop an optimized strategy of haplotype construction using gametes or arrested embryos for PGT-M in pedigrees with single gene diseases and no proband in the setting of difficult cases, which takes into account the expected number of oocytes acquired and the gonadal mosaicism.

02

Conditions studied

  • De Novo Mutation
  • Preimplantation Genetic Testing
  • Without Proband

Keywords

  • preimplantation genetic testing
  • without proband
  • De Novo Mutation
03

In context

Lead sponsor

ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The couples intended for PGT-M without proband were recruited from Shanghai JiAi Genetics and IVF Institute, Obstetrics and Gynecology Hospital of Fudan University between January 2023 and December 2024, and were included in the study if they were expected to have difficulties in the identification of an EAP, typically meeting one of the following criteria:

    1. the carrier of the pathogenic variant was without typical clinical symptoms or detected as gonadosomal mosaic;
    2. the asymptomatic parents, who had one or more children affected with the same disorder, did not possess the genomic alterations carried by the children as per Sanger sequencing or targeted deep sequencing;
    3. female partner with diminished ovarian reserve and therefore a low yield of embryos;
    4. the variants are X-linked and the karyotype of the variant carrier is 47, XXX or 47, XXY etc.

Exclusion criteria

Exclusion Criteria:

  • (1) Non-PGT-M families; (2) Pedigree of other proband samples can be obtained; (3) Patients seeking for PGT-M who strongly request no haplotype analysis in embryos and only require Sanger testing after being fully informed of the risk.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    PGT-M

    The couples intended for PGT-M without proband were recruited from Shanghai JiAi Genetics and IVF Institute, Obstetrics and Gynecology Hospital of Fudan University between January 2023 and December 2024, and were included in the study if they were expected to have difficulties in the identification of an embryo as proband.

    Diagnostic Test: Gametes (sperm or second polar bodies, MI eggs) or arrested embryos were reserved for identification of a proband

Interventions

  • Diagnostic testGametes (sperm or second polar bodies, MI eggs) or arrested embryos were reserved for identification of a proband

    1. Targeted deep sequencing for mosaicism detection for patients with suspected gonadal mosaicism, eg. Repeated similar abortion due to the same variant while the couple were tested negative for the variant in the peripheral blood. 2. Ovarian stimulation, embryo culture, biopsy and vitrification as routinely used in the IVF clinical practice. 3. Gametes and arrested embryo preservation by the embryo laboratory during embryo culture. 4. Genetic testing, including multiple displacement amplification for WGA, variant sequencing in WGA products and Infinium Chip protocol for amplified DNA and haplotype analysis

    Also known as: Targeted deep sequencing for mosaicism detection, Ovarian stimulation, embryo culture, biopsy and vitrification, Genetic testing

06

What researchers measure

Primary outcomes

  1. Consistence of the PGT-M with prenatal diagnosis with amniocentesis

    whether the PGT-M result of the embryos are consistent with the prenatal genetic testing result of amniocentesis

    Time frame: 16 weeks of gestation

07

Study locations

1 site
08

References and documents

Publications

  • Summerer A, Schafer E, Mautner VF, Messiaen L, Cooper DN, Kehrer-Sawatzki H. Ultra-deep amplicon sequencing indicates absence of low-grade mosaicism with normal cells in patients with type-1 NF1 deletions. Hum Genet. 2019 Jan;138(1):73-81. doi: 10.1007/s00439-018-1961-5. Epub 2018 Nov 26. PubMed 30478644 ↗
  • Xiao M, Shi H, Rao J, Xi Y, Zhang S, Wu J, Zhu S, Zhou J, Xu H, Lei C, Sun X. Combined Preimplantation Genetic Testing for Genetic Kidney Disease: Genetic Risk Identification, Assisted Reproductive Cycle, and Pregnancy Outcome Analysis. Front Med (Lausanne). 2022 Jun 17;9:936578. doi: 10.3389/fmed.2022.936578. eCollection 2022. PubMed 35783601 ↗
  • Wilde AAM, Amin AS. Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy. JACC Clin Electrophysiol. 2018 May;4(5):569-579. doi: 10.1016/j.jacep.2018.03.006. Epub 2018 May 2. PubMed 29798782 ↗
  • Wang Y, Zhai F, Guan S, Yan Z, Zhu X, Kuo Y, Wang N, Zhi X, Lian Y, Huang J, Jia J, Liu P, Li R, Qiao J, Yan L. A comprehensive PGT-M strategy for ADPKD patients with de novo PKD1 mutations using affected embryo or gametes as proband. J Assist Reprod Genet. 2021 Sep;38(9):2425-2434. doi: 10.1007/s10815-021-02188-z. Epub 2021 May 3. PubMed 33939064 ↗

Individual participant data

Plan to share: Yes — The de-identified IPD will be published along with the publications of this study

Supporting information: Study protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Dec 9, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06722313
Lead sponsor
ShangHai Ji Ai Genetics & IVF Institute
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Jan 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Dec 9, 2024

Study contacts

Yilun Sui, MD
principal investigator · Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion